

1 **Circulatory dietary and gut-derived metabolites predict preclinical Alzheimer's disease.**

2 Emily Connell<sup>1</sup>, Saber Sami<sup>1</sup>, Mizanur Khondoker<sup>1</sup>, Anne-Marie Minihane<sup>1</sup>, Matthew G. Pontifex<sup>1</sup>,

3 Michael Müller<sup>1</sup>, Simon McArthur<sup>2</sup>, Gwenaelle Le Gall<sup>1†</sup> and David Vauzour<sup>1†\*</sup>

4 <sup>1</sup> Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia,

5 Norwich NR4 7TJ, United Kingdom.

6 <sup>2</sup> Institute of Dentistry, Faculty of Medicine & Dentistry, Queen Mary University of London, Blizard

7 Institute, London E1 2AT, United Kingdom

8

9 † These authors share senior authorship

10 \* To whom correspondence should be addressed: Dr David Vauzour; email: [D.Vauzour@uea.ac.uk](mailto:D.Vauzour@uea.ac.uk)

11 **Abstract**

12 A key component of disease prevention is the identification of at-risk individuals. Microbial dysbiosis  
13 and microbe-derived metabolites (MDM) can influence the central nervous system, but their role in  
14 disease progression and as prognostic indicators is unknown. To identify preclinical factors associated  
15 with Alzheimer's disease (AD), we compared gut microbiome and metabolome profiles of cognitively  
16 healthy subjects, subjective cognitive impairment (SCI) participants and mild cognitive impairment  
17 (MCI) participants (n=50 per group, matched for age, BMI and sex), targeting metabolites previously  
18 associated with cognitive health (TMAO, bile acids, tryptophan, *p*-cresol and their derivatives). 16S  
19 rRNA bacterial microbiome sequencing and targeted LC-MS/MS were employed for faecal  
20 microbiome speciation and serum MDM quantification. Microbiome beta diversity differed between  
21 healthy controls and SCI participants. Multiple linear regression modelling highlighted five serum  
22 metabolites (indoxyl sulfate, choline, 5-hydroxyindole acetic acid, indole-3-propionic acid (IPA) and  
23 kynurenic acid) significantly altered in preclinical AD. Neuroprotective metabolites, including  
24 choline, 5-hydroxyindole acetic acid and IPA, exhibited lower concentrations in SCI and MCI in  
25 comparison to controls, while the cytotoxic metabolite indoxyl sulfate had higher levels. A Random  
26 Forest algorithm with multiclass classification confirmed and extended our results, identifying six  
27 metabolites (indoxyl sulfate, choline, 5-hydroxyindole acetic acid, IPA, kynurenic acid, kynurenine)  
28 as predictors of early cognitive decline, with an area under the curve of 0.74. In summary, a combined  
29 statistical and machine learning approach identified MDM as a novel composite risk factor for the  
30 early identification of future dementia risk.

31

32 **Keywords:** microbiome, indoxyl sulfate, indole-3-propionic acid, 5-hydroxyindole acetic acid,  
33 choline, kynurenic acid, mild cognitive impairment, subjective cognitive impairment.

## 34 1. Introduction

35 Currently, an estimated 55.2 million people suffer from dementia worldwide, of which Alzheimer's  
36 disease (AD) is the main form<sup>1</sup>. In the absence of an effective strategy to slow or prevent disease  
37 progression, dementia incidence is expected to increase to 152.8 million by 2050. By the time AD is  
38 typically diagnosed, substantial neuronal loss will have occurred across multiple brain regions.  
39 Identifying molecular precursors and biological risk factors at preclinical disease stages would enable  
40 earlier detection and the targeting of regular monitoring and mitigating interventions while prevention  
41 is viable.

42 The contribution of lifestyle factors to cognitive decline and dementia is well documented<sup>2,3</sup>. Diet in  
43 particular has emerged as a key influencer of brain health and AD development, in part by modulating  
44 communication along the microbiota-gut-brain axis. This axis forms a bidirectional communication  
45 system comprising neuronal, endocrine, immune and metabolic signalling mechanisms linking the gut  
46 and the central nervous system (CNS)<sup>4</sup>. Gut microbes regulate this communication via the breakdown  
47 of dietary compounds into bioactive metabolites. Such microbe-derived metabolites (MDM)  
48 subsequently modulate pathways affecting the CNS both directly, by crossing the blood-brain barrier  
49 and indirectly, via modulation of peripheral organ function or vagus nerve stimulation<sup>5</sup>. In the  
50 prodromal stages of AD, for example mild cognitive impairment (MCI), the microbiota-gut-brain axis  
51 becomes dysregulated (i.e., dysbiosis), a change associated with pathological processes such as  
52 neuroinflammation and neural injury, and thought to contribute to accelerating cognitive decline<sup>6-8</sup>.  
53 However, the mechanism(s) underlying these changes, and the role of MDM in this process remains  
54 unknown.

55 Several examples of MDM have been linked to cognitive health<sup>5</sup>, including trimethylamine N-oxide  
56 (TMAO)<sup>9-12</sup>, bile acids (BAs)<sup>13-15</sup>, tryptophan<sup>16-19</sup>, *p*-cresol and its derivatives<sup>20,21</sup>. Notably, these  
57 same MDM have been further linked to pathological processes known to be associated with AD<sup>21-28</sup>,  
58 including neuroinflammation, synaptic damage and blood-brain barrier disruption, but whether  
59 changes in these MDM are drivers or correlates of disease processes requires comprehensive  
60 investigation.

61 Targeted metabolomics presents a powerful tool to comprehensively assess changes in the  
62 endogenous metabolome. Here, we present a targeted metabolomics approach employing liquid  
63 chromatography-tandem mass spectrometry (LC-MS/MS) to quantify TMAO, BAs, tryptophan and *p*-  
64 cresol metabolite profiles in the serum of healthy controls and participants in early cognitive decline.  
65 Early cognitive decline comprises individuals with subjective cognitive impairment (SCI) and mild  
66 cognitive impairment (MCI), the preclinical stages of AD progression. This study presents, for the  
67 first time, the prognostic value of key metabolites in combination and represents one of only a few

68 studies characterising metabolic perturbations in the early stages of cognitive decline, including  
69 participants undergoing the earliest preclinical stage of AD, SCI.

## 70 **2. Materials and methods**

### 71 2.1 Study samples

72 Human serum samples from the baseline measurements of two previously conducted clinical studies  
73 were used: (1) the impact of Cranberries On the Microbiome and Brain in healthy Ageing sTudy  
74 (COMBAT; NCT03679533) and (2) the Cognitive Ageing, Nutrition and Neurogenesis (CANN;  
75 NCT02525198) study. The COMBAT study recruited 60 adults, aged 50-80 years, with no subjective  
76 memory complaints as assessed by the Cognitive Change Index (CCI) questionnaire <sup>29</sup>. The CANN  
77 study recruited 259 participants, aged  $\geq 50$  years, with subjective cognitive impairment (SCI) or mild  
78 cognitive impairment (MCI) based on criteria developed by the National Institute of Aging-  
79 Alzheimers Association, with no indication of clinical dementia <sup>30</sup>. Cognitively healthy adults were  
80 selected from the COMBAT study as a control group, with all groups (controls, SCI and MCI, n=50  
81 per group) matched for age, BMI and sex as these are key variables known to affect microbiome  
82 composition <sup>31,32</sup>. Participants with chronic fatigue syndrome, liver disease, diabetes mellitus, or gall  
83 bladder abnormalities were excluded.

84 Cognitive health was assessed using a variety of cognitive tests in both the COMBAT and CANN  
85 study. However, only the Trail Making Test (assessing visual processing speed, scanning, mental  
86 flexibility, as well as executive function) and the digit span test (assessing verbal short-term and  
87 working memory) were used across the COMBAT and CANN studies enabling comparisons.  
88 Participants also completed a validated, semi-quantitative Scottish Collaborative Group (SCG) food  
89 frequency questionnaire (version 6.6) to assess background diet <sup>33</sup>. Biochemical analyses of blood  
90 glucose, liver function (bilirubin, albumin, aspartate aminotransferase (AST), alanine  
91 aminotransferase (ALT) and AST/ALT ratio), kidney function (creatinine) and serum lipid  
92 concentrations (total-, LDL-, HDL-cholesterol and triglyceride) were conducted in all participants.  
93 The protocols were approved by the UK National Research Ethics Service (NRES) Committee, (Study  
94 ID: 14/EE/0189) for CANN and by the University of East Anglia's Faculty of Medicine and Health  
95 Sciences Ethical Review Committee (Reference: 201819-039) and the UK Health Research Authority  
96 (IRAS number: 237251) for COMBAT. The participants provided written informed consent to  
97 participate.

98

### 99 2.2 Microbiome Profiling

100 Microbiome analysis was performed by 16S rRNA sequencing as previously reported<sup>34</sup>. In brief,  
101 DNA extraction was performed from approximately 50 mg of faecal content using the QIAamp  
102 PowerFecal Pro DNA Kit (Qiagen, Manchester, UK) as per the manufacturer's instructions. DNA  
103 quantity was evaluated using a Nanodrop 2000 Spectrophotometer (Fisher Scientific, UK). Quality  
104 assessment by agarose gel electrophoresis distinguished the DNA integrity, purity, fragment size and  
105 concentration. Illumina NovaSeq 6000 PE250 was used to amplify the V3–V4 hypervariable region.  
106 Sequence analysis was carried out using Uparse software (Uparse v7.0.1001)<sup>35</sup>, incorporating all the  
107 effective tags. Sequences sharing a similarity of  $\geq 97\%$  were grouped into the same Operational  
108 Taxonomic Unit (OTU). A representative sequence for each OTU was screened for further annotation.  
109 A representative OTU sequence was further analysed using the SSUrRNA database of SILVA  
110 Database 138<sup>36</sup>. OTU abundance data were normalised using a standard sequence number  
111 corresponding to the sample with the least sequences. Alpha diversity was assessed using both Chao1  
112 and Shannon H diversity indices, whilst beta diversity was assessed using Bray–Curtis dissimilarity.  
113 Statistical significance was determined by Kruskal–Wallis or Permutational Multivariate Analysis of  
114 Variance (PERMANOVA). Comparisons at the phylum and genus level were made using classical  
115 univariate analysis using Kruskal–Wallis combined with a false discovery rate (FDR) approach used  
116 to correct for multiple testing. P-values below 0.05 were considered statistically significant.

117

### 118 2.3 Metabolite Profiling

119 Serum samples were diluted with methanol at a ratio of 1:10 (v/v) and placed on dry ice for 10 min.  
120 Samples were then centrifuged (5 min, 16,000x g at room temp), supernatants filtered using a 0.45  
121  $\mu\text{M}$  PTFE syringe filter and evaporated to dryness using a Savant<sup>TM</sup> SpeedVac<sup>TM</sup> High-Capacity  
122 Concentrator (ThermoFisher, UK). Dried samples were resuspended in either 50  $\mu\text{L}$  of methanol with  
123 the addition of 15  $\mu\text{L}$  of lithocholic acid-d4 and cholic acid-d4 at 50  $\mu\text{g}/\text{mL}$  for the detection of bile  
124 acids, 50  $\mu\text{L}$  water with TMA-d9 N-oxide, TMA 13C 15N hydrochloride at 50  $\mu\text{g}/\text{mL}$  for the  
125 detection of TMAO/TMA/choline or 50  $\mu\text{L}$  water with 15  $\mu\text{L}$  of L-methionine-3, 3, 4, 4 d4 and p-  
126 toluenesulfonic acid at 50  $\mu\text{g}/\text{mL}$  for the detection of tryptophan and *p*-cresol metabolites  
127 respectively. All internal standards were supplied by ThermoFisher, UK. Samples were analysed using  
128 the Waters Acquity UPLC system and Xevo TQ-S Cronos mass spectrometer with MassLynx 4.1  
129 software. See supplementary methods for full details.

130

### 131 2.4 Statistical Analyses

132 Significant associations of metabolites with cognitive status were identified using multiple linear  
133 regression analysis. Covariates known to affect metabolome or microbiome composition, including  
134 age, BMI, diet and markers of kidney function (creatinine) and liver function (AST/ALT ratio), were

135 included in the model<sup>37-41</sup>. Sex was not included as a covariate as all groups had an equal proportion  
136 of males and females. Diet was assessed using a validated, semi-quantitative Scottish Collaborative  
137 Group (SCG) food frequency questionnaire (version 6.6)<sup>33</sup>. Participants' dietary components were  
138 grouped (kcal, proteins, fats, carbohydrates, water, alcohol, vitamins and minerals) and analysed using  
139 hierarchical clustering via Ward's linkage method to assemble individuals with similar dietary  
140 patterns (Supplementary Figure S1). This clustered participants into low, moderate and high intake of  
141 dietary components and was added to the model as a categorical variable, with participants with a  
142 moderate intake used as a reference group. Age, BMI, creatinine and AST/ALT ratio were added to  
143 the model as continuous variables. Finally, cognitive status (i.e., control, SCI and MCI) was added to  
144 the model as a categorical variable. Metabolite concentrations outside  $\pm 2$  standard deviations from  
145 the mean were excluded as outliers. The assumptions for multiple linear regression analysis including  
146 the existence of a linear relationship among the outcome and predictor variable, normality and  
147 homoscedasticity were assessed (Supplementary Figure S2). The model tested for significant  
148 associations between metabolite and cognitive status, adjusting for the included covariates. All  
149 multiple linear regression analyses were performed in R (v3.6.3; R Foundation: A Language and  
150 Environment for Statistical Computing).

151

## 152 2.5 Machine Learning

153 A Random Forest (RF) machine learning algorithm was implemented to assess whether metabolites  
154 could be predictive of preclinical AD. The RF model was constructed using 100 decision trees and 6  
155 random variables considered at each split. The number of variables considered per split corresponds to  
156 the square root of the total number of attributes in the data<sup>42</sup> (as 32 variables were considered, this  
157 resulted in ~6 random variables per split). To create a composite panel to predict preclinical AD,  
158 metabolites were ranked according to the mean decrease Gini. This highlights the loss in model  
159 performance when permuting the predictor values, and can provide more robust results than mean  
160 decrease accuracy<sup>43</sup>. The metabolites with the highest mean decrease Gini score producing the  
161 highest AUC values were retained in the model. To compare our model, Naive Bayes and AdaBoost  
162 machine learning models were also constructed<sup>44,45</sup>. AdaBoost predictions were made by using a  
163 weighted average of weak classifiers. Our model contained 50 estimators, a learning rate of 1.00 and a  
164 SAMME classification algorithm which updated the base estimator's weights with classification  
165 results. The Naive Bayes method was applied based on applying Bayes' theorem with the "naive"  
166 assumption of conditional independence between every pair of features given the value of the target  
167 variable. The dataset for multi-class classification was randomly divided into training and testing,  
168 with 75% of the samples allocated to the training set and 25% to the testing set. Models were assessed  
169 by the average area under the receiver operator curve (AUC) (plotting the false positive rate against

170 the true positive rate) over all classes (macro-average) as an indication of model performance. All  
171 machine learning models were built in Python (Python Software Foundation. Python Language  
172 Reference, version 3.8).

173

### 174 **3. Results**

#### 175 3.1 Study population characteristics

176 A total of 150 individuals were included in the study of which 50 (33.3%) were cognitively healthy,  
177 50 (33.3%) presented with SCI and 50 (33.3%) with MCI. The mean  $\pm$  SD age of all participants was  
178  $65.5 \pm 5.7$  years, with a mean level of education of  $14.6 \pm 3.5$  years and 54% female (Table 1).  
179 Cognitive groups were matched for age, BMI and sex ( $p= 0.99$ ). Participants in both the COMBAT  
180 and CANN study undertook several cognitive assessments at their baseline visit <sup>29,30</sup>. Significant  
181 differences were found in the Trail Making Test B, digit span backward test and digit span total score  
182 between groups ( $p<0.05$ ). There was a marginal difference between the three groups in the Trail  
183 Making Test A ( $p= 0.09$ ) and no significant difference occurred in the digit span forwards test ( $p=$   
184  $0.21$ ). The prevalence of the *APO*  $\epsilon 4$  was lower in controls (18%) compared to SCI (26%) and MCI  
185 (38%) participants.

186 Albumin, bilirubin and fasting glucose ( $p<0.01$ ) differed according to cognitive status. Interestingly,  
187 both albumin and bilirubin were highest in controls and lowest in SCI participants. Although  
188 participants diagnosed with diabetes mellitus were excluded, fasting glucose increased over  
189 preclinical AD, with the lowest concentrations in control individuals and the highest in MCI (Table  
190 1).

191

#### 192 3.2 Gut microbiome and metabolome shifts in preclinical AD

193 Alpha diversity was measured using the Chao1 ( $p= 0.21$ ) and Shannon H ( $p= 0.70$ ) indices with no  
194 significant difference amongst groups (Figure 1A-B). Conversely, beta diversity, as measured by  
195 Bray-Curtis dissimilarity, was significantly different (PERMANOVA F-value= 1.35,  $p= 0.02$ ) (Figure  
196 1C). Pairwise analysis suggested the shift was primarily driven by the differences between the control  
197 and SCI groups (FDR  $q= 0.03$ ), rather than between SCI and MCI (FDR  $q= 0.38$ ) or MCI and control  
198 (FDR  $q= 0.15$ ) (Figure 1D). The PLS-DA plot suggested similar patterns in participants' metabolomic  
199 profiles, with control separating from SCI and MCI (Figure 2A). The extent of this separation can be  
200 seen through the heatmap displaying shifts in metabolite concentrations between groups and  
201 clustering SCI and MCI together (Figure 2B). The similarity between microbiome and metabolomic  
202 profiles was confirmed by conducting a Procrustes analysis to evaluate the congruence of the two

203 datasets. The analysis revealed strong similarity between the metabolome and microbiome results in  
204 control and SCI (R= 0.21, p= 0.03), SCI and MCI (R= 0.27, p= 0.002) and MCI and control (R= 0.26,  
205 p= 0.002) groups (Supplementary Figure S3).

206

207 3.3 Serum metabolites significantly associated with early cognitive decline in an adjusted  
208 multivariable model

209 Multiple linear regression analysis adjusted for liver function (AST/ALT ratio), kidney function  
210 (creatinine), age, BMI and background diet identified five metabolites significantly associated with  
211 early cognitive decline, including choline, 5-hydroxyindole acetic acid, indole-3- propionic acid  
212 (IPA), indoxyl sulfate and kynurenic acid (Table 1). Indoxyl sulfate, choline and 5-hydroxyindole  
213 acetic acid were associated with both SCI and MCI (p<0.05). Kynurenic acid was significantly  
214 associated with SCI ( $\beta$ = 0.007, 95% CI: <0.001, 0.014, p= 0.037) but not MCI ( $\beta$ = 0.001, 95% CI: -  
215 0.006, 0.007, p= 0.874). On the other hand, IPA was significantly associated with MCI ( $\beta$ = -0.558,  
216 95% CI: -0.910, -0.206, p= 0.002), but not SCI ( $\beta$ = -0.181, 95% CI: -0.536, 0.174, p= 0.316).  
217 Neuroprotective metabolites, including choline, 5-hydroxyindole acetic acid and indole propionic acid  
218 <sup>46-48</sup>, exhibited lower concentrations in SCI and MCI participants in comparison to controls, while  
219 metabolites linked to cytotoxicity, including indoxyl sulfate, showed increasing levels <sup>49</sup>. Kynurenic  
220 acid, a typically neuroprotective metabolite <sup>50</sup>, was higher in SCI and MCI in comparison to controls.  
221 Group means for all metabolite concentrations are given in Supplementary Table S1.

222

223 3.4 Machine learning models to identify risk factors predictive of preclinical AD

224 All 32 serum metabolites were initially evaluated as possible predictors of preclinical AD. RF  
225 achieved the highest classification AUC of 0.65, with AdaBoost and Naïve Bayes attaining 0.58 and  
226 0.63 respectively (Supplementary Table S2). Using the mean decrease Gini, the importance of each  
227 metabolite was assessed (Figure S4). Six metabolites (5-hydroxyindole acetic acid, indole-3-propionic  
228 acid, choline, indoxyl sulfate, kynurenic acid and kynurenine) produced the highest AUC of 0.74  
229 using the RF classification algorithm (Figure 4). In comparison, Naive Bayes achieved an AUC of  
230 0.72 and AdaBoost attained 0.68. The RF ROC curve indicated the model's predictive performance  
231 was highest for controls (AUC= 0.79), followed by MCI (AUC= 0.76) and SCI (AUC= 0.64). As  
232 such, we investigated whether the model performance would be improved by predicting only healthy  
233 ageing and MCI. Using the six serum metabolites from controls and MCI participants, the RF model  
234 showed improved predictive performance (AUC= 0.84) (Supplementary Table S2). AdaBoost and  
235 Naive Bayes also demonstrated increased performance, attaining AUC of 0.87 and 0.90 respectively.

236



237 3.5 Serum dietary and MDM and gut microbiome modulation in preclinical AD are significantly  
238 linked

239 Having identified a shift in both the microbiome and metabolome profiles, a Spearman correlation  
240 examined possible connections between the two datasets. Significantly modulated metabolites and  
241 microbiome genera between the three groups ( $p < 0.05$ ) were correlated, revealing bacterial–metabolite  
242 interactions. Control and SCI participants displayed a negative relationship between 5-hydroxyindole  
243 acetic acid and *Lachnoclostridium* ( $R = -0.29$ ,  $p = 0.004$ ), indoxyl sulfate and *Turicibacter* ( $R = -0.21$ ,  
244  $p = 0.038$ ), and choline and *Lachnoclostridium* ( $R = -0.36$ ,  $p = 0.0002$ ) and *Ruminococcus gnavus* group  
245 ( $R = -0.28$ ,  $p = 0.005$ ) (Figure 3A). Choline and *UCG-009* ( $R = 0.316$ ,  $p = 0.002$ ), anthranilic acid and  
246 *Lactonifactor* ( $R = 0.24$ ,  $p = 0.019$ ) and *Holdemanella* ( $R = 0.24$ ,  $p = 0.02$ ), indoxyl sulfate and  
247 *Holdemania* ( $R = 0.318$ ,  $p = 0.001$ ) and *Lactonifactor* ( $R = 0.33$ ,  $p = 0.0008$ ) had a positive correlation.  
248 Between SCI and MCI participants, only IPA and *Lachnospiraceae ND3007* group had a positive  
249 correlation ( $R = 0.26$ ,  $p = 0.011$ ) (Figure 3B).

250 As indoxyl sulfate, choline, 5-hydroxyindole acetic acid and IPA were identified as risk factors of  
251 cognitive decline, genera correlated with these metabolites were investigated further to identify  
252 potential associations with their production. *Holdemania* and *Lachnoclostridium* genera were higher  
253 in SCI participants in comparison to controls but lower in SCI relative to MCI (Figure 3C-D). On the  
254 other hand, *Turicibacter* were higher in both SCI and MCI participants in comparison to controls  
255 (Figure 3E). The abundance of *UCG-009* was significantly lower in both SCI and MCI participants in  
256 comparison to controls (Figure 3F). *Lactonifactor* and *Ruminococcus gnavus* were both higher in SCI  
257 in comparison to controls (Figure G-H). Finally, *Lachnospiraceae ND3007* was not different between  
258 control and SCI but was lower in SCI compared to MCI (Figure 3I).

#### 259 260 **4. Discussion**

261 Identification of robust, inexpensive and non-invasive markers of cognitive status and its trajectory is  
262 currently an unmet medical need in AD research, with circulating gut-derived metabolites presenting  
263 a promising area. Metabolic alterations contain rich systemic information on the underlying  
264 physiology that connects the periphery to the CNS, likely affecting numerous pathways  
265 simultaneously. Thus, the simultaneous detection of numerous perturbed metabolites can provide a  
266 powerful detection tool. However, studies investigating composite markers are lacking.

267 16s rRNA sequencing indicated that significant shifts in gut microbiome composition occur during  
268 preclinical AD, commencing as early as SCI, suggesting changes may already be apparent when  
269 memory complaints first appear, aligning with previous studies<sup>51,52</sup>. As cognitive decline progresses  
270 from SCI to MCI, gut microbiome modulation appears to be less significant. Circulatory metabolites

271 also reflect this pattern, clustering SCI and MCI participants independently from the healthy controls.  
272 Individuals with SCI are likely at a higher risk of cognitive decline progression compared to those  
273 who are cognitively healthy<sup>53</sup>, which may lead to greater alterations in biological markers, including  
274 the gut microbiome and its metabolites. Procrustes analysis showed significant congruence of the  
275 microbiome and metabolome datasets, suggesting the two are interlinked and provides the potential  
276 for MDM predictors to be detected early in disease progression. Indeed, gut microbiome composition  
277 can account for up to 58% of the variation of circulatory metabolites communicating along the  
278 microbiota-gut-brain axis<sup>54</sup>.

279 Targeted metabolomics quantifies metabolites with extremely high sensitivity and accuracy, providing  
280 an advantage over the relative responses yielded by untargeted approaches. RF and multiple linear  
281 regression models both revealed indoxyl sulfate, choline, 5-hydroxyindole acetic acid, IPA and  
282 kynurenic acid as key early indicators of cognitive decline, with RF presenting an AUC predictive  
283 performance of 0.74, strongly supporting a significant link between metabolic perturbations  
284 associated with the gut microbiome and preclinical AD progression. Previous studies have  
285 predominantly concentrated on binary classification approaches, primarily utilising MRI and PET  
286 imaging modalities, to investigate AD progression<sup>55-57</sup>. However, in clinical practice, multiclass  
287 classification of blood samples of patients with SCI, MCI and healthy controls could provide a useful  
288 approach. Tong and colleagues attained a similar predictive performance (AUC= 0.729) using RF and  
289 nonlinear graph fusion of multiple modalities (regional MRI volumes, voxel-based FDG-PET signal  
290 intensities, CSF biomarker measures and genetic information) to classify control, MCI and AD  
291 participants<sup>58</sup>. AUC increased to 0.84 when predicting healthy ageing and MCI, likely due to the  
292 difficulty of diagnosing a patient undergoing SCI. Indeed, Purser and colleagues found no relationship  
293 between memory complaints and the progression of cognitive impairment over 10 years in individuals  
294 65 years and over<sup>59</sup>. However, others dispute this result<sup>60</sup>. Adjusting our statistical analysis for  
295 confounding variables that heavily influence the host, such as age, BMI, kidney function, liver  
296 function and background diet, improves analysis robustness and sensitivity. Adjusting for background  
297 diet becomes particularly vital when examining MDM as the diet can both modulate gut microbiome  
298 composition and provide a variety of bioactive precursor compounds; a factor which is often  
299 overlooked in metabolomic analyses<sup>61</sup>. Nevertheless, our results highlight the use of profiling select  
300 circulatory MDM to identify higher-risk individuals of cognitive decline.

301 Of the five metabolites highlighted by both machine learning and multiple linear regression, all except  
302 choline are produced from tryptophan metabolism, indicating notable alterations in tryptophan  
303 metabolism may occur in preclinical AD progression. Tryptophan metabolism has previously been  
304 well-linked to AD<sup>18</sup>. Indeed, we find lower neuroprotective tryptophan-derived metabolites, including  
305 IPA and 5-hydroxyindole acetic acid, as cognitive decline progresses from controls to SCI and MCI.  
306 IPA is produced in the gut by the microbial conversion of tryptophan via the indole pathway and has

307 previously been investigated as a possible treatment for AD<sup>62</sup> due to its potent antioxidant effect  
308 against A $\beta$  1-42 *in vitro*<sup>63</sup> and its ability to prevent aggregation and deposition of A $\beta$  monomers<sup>64</sup>.  
309 IPA is anti-inflammatory, reducing the concentration of the proinflammatory TNF- $\alpha$  in activated  
310 microglia<sup>65</sup>, lowering the expression of chemokine (CC Motif) ligand 2 (CCL2) and nitric oxide  
311 synthase 2 (NOS2) in interferon-beta (IFN- $\beta$ ) activated murine astrocytes<sup>66</sup> and preventing increases  
312 in cytokines in LPS-induced human primary astrocytes<sup>67</sup>, and has previously been identified as a  
313 predictor of AD progression<sup>68</sup>. 5-hydroxyindole acetic acid is often used as a surrogate marker for  
314 serotonin due to serotonin's rapid degradation. As such, our findings indicate lower peripheral  
315 serotonin breakdown as early cognitive decline progresses. Approximately 95% of all serotonin is  
316 localised in peripheral compartments where it is involved in the modulation of the enteric nervous  
317 system (ENS) development and neurogenesis, gut motility, secretion, inflammation, and epithelial  
318 development, suggesting these processes may be disrupted in early cognitive decline<sup>69</sup>. Indeed, MCI  
319 and AD patients have often been reported to suffer from gastrointestinal symptoms<sup>70</sup> and ENS  
320 dysregulation in AD has previously been described<sup>71</sup>. Decreased concentrations of 5-hydroxyindole  
321 acetic acid also suggest a shift in tryptophan metabolism towards the kynurenine pathway, reducing  
322 the availability of tryptophan for serotonin synthesis. This is supported by higher serum kynurenine  
323 concentrations in SCI and MCI participants in comparison to controls (Supplementary Table S1) and  
324 has previously been found in AD participants, linked to poor memory, executive function and global  
325 cognition<sup>72</sup>. The kynurenine pathway is activated by an inflammatory stimulus, promoting  
326 indoleamine 2,3-dioxygenase, the rate-limiting enzyme that initiates the kynurenine pathway.  
327 Increased inflammation is a common feature of AD and as such may play a role in modulating  
328 tryptophan catabolites.

329 Both indoxyl sulfate and kynurenic acid concentrations were increased as cognitive decline  
330 progressed, even after adjusting for measures of liver and kidney function. As a uremic toxin, indoxyl  
331 sulfate can disrupt neuronal efflux transport systems, promote the production of free radicals,  
332 inflammation, endothelial cell dysfunction and disturb the circadian rhythm involved in clearing renal  
333 and CNS toxins<sup>73,74</sup>, likely contributing to cognitive decline. Serum levels of indoxyl sulfate, as well  
334 as albumin, have previously been identified as predictive of cognitive impairment in participants with  
335 end-stage renal disease<sup>75</sup>. End-stage renal disease patients have also been reported to have an  
336 increased abundance of the gut bacteria *Holdemania*, in line with our results, suggesting his genera  
337 may be underlying the changes between control and SCI<sup>76</sup>. Rodent studies show increased kynurenic  
338 acid concentrations can impair cognitive function, including spatial working memory, and broad  
339 monitoring deficits<sup>77,78</sup>. However, data regarding this relationship in human studies is inconsistent  
340<sup>79,80</sup>. Kynurenic acid can play a protective role against the cytotoxic product of the kynurenine  
341 pathway, quinolinic acid, by acting as an NMDA antagonist for both glycine and glutamate  
342 modulatory sites<sup>81</sup>. However, abnormal accumulation has previously been found to induce

343 glutamatergic hypofunction and subsequently disrupt cognitive function<sup>82</sup>. In AD, increased blood  
344 concentrations of kynurenic acid have been hypothesised to relate to neuroinflammatory processes  
345 and may be produced as a protective response to neuronal damage<sup>83</sup>.

346 Choline is required for numerous biological functions in the body<sup>84</sup>, notably including hallmark AD-  
347 associated processes such as acetylcholine synthesis<sup>85</sup>. As choline readily crosses the blood-brain  
348 barrier, peripheral concentrations typically mirror concentrations in the brain<sup>86</sup>, thus lower  
349 concentrations in early cognitive decline may indicate decreased central acetylcholine production.  
350 Acetylcholine is intricately connected to neural networks regulating memory, and a reduction in this  
351 system is closely associated with learning and memory deficits in AD<sup>87</sup>. *Lachnoclostridium* and  
352 *Lactonifactor* were inversely correlated with choline levels, suggesting changes in these genera may  
353 modulate blood concentrations. Indeed, previous research has found *L. saccharolyticum* WM1, a  
354 representative strain of *Lachnoclostridium*, to be an efficient converter of choline to TMA *in vitro*,  
355 transforming at a rate near 100%<sup>88</sup>. This metabolic process *in vivo* also elevated serum TMAO levels  
356<sup>88</sup>, which is supported by our results displaying a 1.6-fold higher TMAO in MCI compared to  
357 controls. It is likely that increases in *Lachnoclostridium* abundance may increase the metabolism of  
358 choline to TMAO, decreasing its concentration in circulation.

359 Our study has major strengths including simultaneously targeting some of the top microbial and  
360 metabolic metabolites associated with cognitive decline, whilst matching our participants and  
361 adjusting our analysis for key factors known to influence the metabolome (age, BMI, sex, liver  
362 function, kidney function and background diet), factors rarely accounted for in marker studies.  
363 Furthermore, our study highlights key microbiota underlying these metabolic changes, as well as  
364 investigating participants from the earliest stage of decline (SCI) and validating our results through  
365 machine learning and adjusted statistical approaches. However, some limitations should be stressed.  
366 Despite our study adjusting results for key covariates, host metabolome profiles are influenced by a  
367 plethora of additional largely environmental and biological factors. Thus, although our findings  
368 suggest relationships between the variables, we cannot infer causal relationships from this analysis  
369 alone. Moreover, participants' background diet was adjusted for using data collected by food  
370 frequency questionnaires, which can be prone to measurement error and may introduce inaccuracies  
371 due to recall bias and self-reporting issues. Furthermore, like all studies utilising machine learning  
372 models, the larger the dataset, the more robust the predictive performance. With the current dataset  
373 including 150 individuals and 32 metabolites, we achieved significant predictive performance.  
374 However, our findings will require external validation in larger independent cohorts to improve the  
375 model.

376 Pathophysiological progression of AD is apparent up to 20 years prior to clinical symptom onset,  
377 making it vital for prevention research to focus on uncovering novel preclinical risk factors. Scalable

378 markers that enable the early detection of at-risk persons could permit the targeting of lifestyle  
379 interventions to lessen future risk and uncover novel mechanisms underpinning dementia. Our  
380 findings present new insights into the preclinical progression of cognitive decline and dementia. We  
381 signify a major role for the gut in connection to the brain through the modulation of key MDM.  
382 Furthermore, we lend strength to the hypothesis that individuals with higher risks of cognitive decline  
383 can be identified via a targeted metabolomic approach in the preceding stages of AD.

384 **Data availability**

385 The 16S rRNA gene sequence data have been deposited in the NCBI BioProject database  
386 (<https://www.ncbi.nlm.nih.gov/bioproject/>) under accession number PRJNA1109848. Other data that  
387 support the findings of this study are available from the corresponding authors upon reasonable  
388 request.

389

390 **Authors Contributions**

391 D.V. conceptualised the project. A.M.M. provided the human blood and faecal samples. G.L.G.  
392 designed the metabolomic analysis, which E.C. and G.L.G. then performed. E.C. conducted the 16S  
393 rRNA microbiome sequencing. E.C. and S.S. performed the machine learning analysis. E.C. and M.K.  
394 conducted the statistical analysis. E.C. wrote the paper. D.V., S.S., M.K., A.M.M., M.G.P., M.M.,  
395 S.M. G.L.G. contributed key discussions in interpreting results and edited the paper. All authors  
396 approved the final version of the paper.

397 **Figure Legends**

398 **Figure 1: Microbiome beta diversity is significantly altered in early cognitive decline.** Alpha  
399 diversity measured by Chao1 (A) and Shannon H (B) index. (C) Beta diversity as measured by Bray-  
400 curtis; p-value generated from PERMANOVA. (D) Pairwise comparisons of the beta diversity  
401 analysis.

402 **Figure 2: Metabolic shift occurs in early cognitive decline.** (A) Partial least squares-discriminant  
403 analysis (PLS-DA) plot of the metabolomic profiles. (B) Heatmap displaying changes in  
404 concentrations of metabolites between the groups, with hierarchical clustering.

405 **Figure 3: Serum metabolome and gut microbiome profiles are linked.** Spearman rank correlation  
406 analysis between metabolite and microbiome genera that are significantly modulated in early  
407 cognitive decline (A) between control and SCI and (B) between SCI and MCI. (C-H) Abundance  
408 counts of microbiome genera correlated with our metabolites of interest (indoxyl sulfate, choline and  
409 5-hydroxyindole acetic acid) between control and SCI participants. (I) Abundance count of  
410 microbiome genera correlated with metabolite of interest (indole-3-propionic acid) between SCI and  
411 MCI, \*=p<0.05, \*\*=p<0.01.

412 **Figure 4: Six circulatory metabolites are predictive of preclinical AD.** Receiving Operating  
413 Characteristic (ROC) curve illustrating the performance of the Random Forest model for classifying  
414 controls, SCI and MCI participants with average area under the curve (AUC) of the multilevel  
415 classifier.

416 **5. References**

417

- 418 1. World Health Organization. Global status report on the public health response to dementia.  
419 *Security Research Hub Reports* (2021).
- 420 2. Flicker, L. Modifiable Lifestyle Risk Factors for Alzheimer's Disease. *Journal of Alzheimer's*  
421 *Disease* **20**, 803–811 (2010).
- 422 3. Livingston, G. *et al.* Dementia prevention, intervention, and care: 2020 report of the Lancet  
423 Commission. *The Lancet* **396**, 413–446 (2020).
- 424 4. Chakrabarti, A. *et al.* The microbiota-gut-brain axis: pathways to better brain health. Perspectives  
425 on what we know, what we need to investigate and how to put knowledge into practice. *Cell Mol*  
426 *Life Sci* **79**, 80 (2022).
- 427 5. Connell, E. *et al.* Microbial-derived metabolites as a risk factor of age-related cognitive decline  
428 and dementia. *Molecular Neurodegeneration* **17**, 43 (2022).
- 429 6. Li, B. *et al.* Mild cognitive impairment has similar alterations as Alzheimer's disease in gut  
430 microbiota. *Alzheimer's & Dementia* **15**, 1357–1366 (2019).
- 431 7. Liu, P. *et al.* Altered microbiomes distinguish Alzheimer's disease from amnesic mild cognitive  
432 impairment and health in a Chinese cohort. *Brain, Behavior, and Immunity* **80**, 633–643 (2019).
- 433 8. Nagpal, R. *et al.* Gut mycobiome and its interaction with diet, gut bacteria and alzheimer's  
434 disease markers in subjects with mild cognitive impairment: A pilot study. *EBioMedicine* **59**,  
435 102950 (2020).
- 436 9. Brunt, V. E. *et al.* The gut microbiome-derived metabolite trimethylamine N-oxide modulates  
437 neuroinflammation and cognitive function with aging. *GeroScience* **43**, 377–394 (2021).
- 438 10. Li, D. *et al.* Trimethylamine-N-oxide promotes brain aging and cognitive impairment in mice.  
439 *Aging Cell* **17**, e12768 (2018).
- 440 11. Zhuang, Z. *et al.* Causal relationships between gut metabolites and Alzheimer's disease: a  
441 bidirectional Mendelian randomization study. *Neurobiology of Aging* **100**, 119.e15-119.e18  
442 (2021).



- 443 12. Hoyles, L. *et al.* Regulation of blood-brain barrier integrity by microbiome-associated  
444 methylamines and cognition by trimethylamine N-oxide. *Microbiome* **9**, 235 (2021).
- 445 13. Baloni, P. *et al.* Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and  
446 Metabolism in Alzheimer's Disease. *Cell Rep Med* **1**, 100138 (2020).
- 447 14. MahmoudianDehkordi, S. *et al.* Altered Bile Acid Profile Associates with Cognitive Impairment  
448 in Alzheimer's Disease – An Emerging Role for Gut Microbiome. *Alzheimers Dement* **15**, 76–92  
449 (2019).
- 450 15. Nho, K. *et al.* Altered Bile Acid Profile in Mild Cognitive Impairment and Alzheimer's Disease:  
451 Relationship to Neuroimaging and CSF Biomarkers. *Alzheimers Dement* **15**, 232–244 (2019).
- 452 16. Hestad, K., Alexander, J., Rootwelt, H. & Aaseth, J. O. The Role of Tryptophan Dysmetabolism  
453 and Quinolinic Acid in Depressive and Neurodegenerative Diseases. *Biomolecules* **12**, 998  
454 (2022).
- 455 17. Schwarcz, R., Bruno, J. P., Muchowski, P. J. & Wu, H.-Q. Kynurenines in the mammalian brain:  
456 when physiology meets pathology. *Nat Rev Neurosci* **13**, 465–477 (2012).
- 457 18. Weaver, D., Gupta, M., Meek, A., Wang, Y. & Wu, F. Alzheimer's Disease as a Disorder of  
458 Tryptophan Metabolism (2745). *Neurology* **94**, (2020).
- 459 19. Whiley, L. *et al.* Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and  
460 kynurenine pathway metabolites in both the urine and serum of individuals living with  
461 Alzheimer's disease. *Alzheimer's Research & Therapy* **13**, 20 (2021).
- 462 20. Sankowski, B. *et al.* Higher cerebrospinal fluid to plasma ratio of p-cresol sulfate and indoxyl  
463 sulfate in patients with Parkinson's disease. *Clinica Chimica Acta* **501**, 165–173 (2020).
- 464 21. Shah, S. N. *et al.* Cerebrovascular damage caused by the gut microbe-derived uraemic toxin p-  
465 cresol sulfate is prevented by blockade of the epidermal growth factor receptor.  
466 2022.11.12.516113 Preprint at <https://doi.org/10.1101/2022.11.12.516113> (2022).
- 467 22. Smith, M. J., Crowther, R. A. & Goedert, M. The natural osmolyte trimethylamine N-oxide  
468 (TMAO) restores the ability of mutant tau to promote microtubule assembly. *FEBS Lett* **484**,  
469 265–270 (2000).

- 470 23. Jena, P. K. *et al.* Dysregulated bile acid synthesis and dysbiosis are implicated in Western diet-  
471 induced systemic inflammation, microglial activation, and reduced neuroplasticity. *FASEB J* **32**,  
472 2866–2877 (2018).
- 473 24. Tran, C. D. *et al.* Gut permeability, its interaction with gut microflora and effects on metabolic  
474 health are mediated by the lymphatics system, liver and bile acid. *Future Microbiology* **10**, 1339–  
475 1353 (2015).
- 476 25. Azevedo, M. L. V. *et al.* p-Cresyl sulfate affects the oxidative burst, phagocytosis process, and  
477 antigen presentation of monocyte-derived macrophages. *Toxicol Lett* **263**, 1–5 (2016).
- 478 26. Edamatsu, T., Fujieda, A. & Itoh, Y. Phenyl sulfate, indoxyl sulfate and p-cresyl sulfate decrease  
479 glutathione level to render cells vulnerable to oxidative stress in renal tubular cells. *PLoS One* **13**,  
480 e0193342 (2018).
- 481 27. Sun, C.-Y., Cheng, M.-L., Pan, H.-C., Lee, J.-H. & Lee, C.-C. Protein-bound uremic toxins  
482 impaired mitochondrial dynamics and functions. *Oncotarget* **8**, 77722–77733 (2017).
- 483 28. Tang, W.-H. *et al.* Protein-bounded uremic toxin p-cresylsulfate induces vascular permeability  
484 alternations. *Histochem Cell Biol* **149**, 607–617 (2018).
- 485 29. Flanagan, E. *et al.* Chronic Consumption of Cranberries (*Vaccinium macrocarpon*) for 12 Weeks  
486 Improves Episodic Memory and Regional Brain Perfusion in Healthy Older Adults: A  
487 Randomised, Placebo-Controlled, Parallel-Groups Feasibility Study. *Frontiers in Nutrition* **9**,  
488 (2022).
- 489 30. Irvine, M. A. *et al.* The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial: Design and  
490 progress. *Alzheimers Dement (N Y)* **4**, 591–601 (2018).
- 491 31. Haro, C. *et al.* Intestinal Microbiota Is Influenced by Gender and Body Mass Index. *PLOS ONE*  
492 **11**, e0154090 (2016).
- 493 32. Zhang, X. *et al.* Sex- and age-related trajectories of the adult human gut microbiota shared across  
494 populations of different ethnicities. *Nat Aging* **1**, 87–100 (2021).
- 495 33. Hollis, J. L. *et al.* Assessing the relative validity of the Scottish Collaborative Group FFQ for  
496 measuring dietary intake in adults. *Public Health Nutrition* **20**, 449–455 (2017).

- 497 34. Pontifex, M. G. *et al.* Saffron extract (Safr'Inside™) improves anxiety related behaviour in a  
498 mouse model of low-grade inflammation through the modulation of the microbiota and gut  
499 derived metabolites. *Food Funct.* **13**, 12219–12233 (2022).
- 500 35. Wang, Q., Garrity, G. M., Tiedje, J. M. & Cole, J. R. Naive Bayesian classifier for rapid  
501 assignment of rRNA sequences into the new bacterial taxonomy. *Appl Environ Microbiol* **73**,  
502 5261–5267 (2007).
- 503 36. Quast, C. *et al.* The SILVA ribosomal RNA gene database project: improved data processing and  
504 web-based tools. *Nucleic Acids Res* **41**, D590-596 (2013).
- 505 37. Gowda, S. *et al.* Markers of renal function tests. *N Am J Med Sci* **2**, 170–173 (2010).
- 506 38. Williams, A. L. & Hoofnagle, J. H. Ratio of serum aspartate to alanine aminotransferase in  
507 chronic hepatitis. Relationship to cirrhosis. *Gastroenterology* **95**, 734–739 (1988).
- 508 39. Giannini, E. *et al.* Progressive liver functional impairment is associated with an increase in  
509 AST/ALT ratio. *Dig Dis Sci* **44**, 1249–1253 (1999).
- 510 40. Tavassol, Z. H. *et al.* Alteration in Gut Microbiota Composition of Older Adults Is Associated  
511 with Obesity and Its Indices: A Systematic Review. *The Journal of nutrition, health and aging*  
512 **27**, 817–823 (2023).
- 513 41. Leeming, E. R., Johnson, A. J., Spector, T. D. & Le Roy, C. I. Effect of Diet on the Gut  
514 Microbiota: Rethinking Intervention Duration. *Nutrients* **11**, 2862 (2019).
- 515 42. Liaw, A. & Wiener, M. Classification and Regression by RandomForest. *Forest* **23**, (2001).
- 516 43. Calle, M. L. & Urrea, V. Letter to the editor: Stability of Random Forest importance measures.  
517 *Brief Bioinform* **12**, 86–89 (2011).
- 518 44. Wang, R. AdaBoost for Feature Selection, Classification and Its Relation with SVM, A Review.  
519 *Physics Procedia* **25**, 800–807 (2012).
- 520 45. Rish, I. An Empirical Study of the Naïve Bayes Classifier. *IJCAI 2001 Work Empir Methods Artif*  
521 *Intell* **3**, (2001).
- 522 46. Hwang, I. K. *et al.* Indole-3-propionic acid attenuates neuronal damage and oxidative stress in the  
523 ischemic hippocampus. *J Neurosci Res* **87**, 2126–2137 (2009).

- 524 47. Blusztajn, J. K., Slack, B. E. & Mellott, T. J. Neuroprotective Actions of Dietary Choline.  
525 *Nutrients* **9**, 815 (2017).
- 526 48. Klein, C. *et al.* 5-HIAA induces neprilysin to ameliorate pathophysiology and symptoms in a  
527 mouse model for Alzheimer’s disease. *Acta Neuropathologica Communications* **6**, 136 (2018).
- 528 49. Leong, S. C. & Sirich, T. L. Indoxyl Sulfate—Review of Toxicity and Therapeutic Strategies.  
529 *Toxins* **8**, 358 (2016).
- 530 50. Ostapiuk, A. & Urbanska, E. M. Kynurenic acid in neurodegenerative disorders—unique  
531 neuroprotection or double-edged sword? *CNS Neurosci Ther* **28**, 19–35 (2021).
- 532 51. Sheng, C. *et al.* Altered Gut Microbiota in Adults with Subjective Cognitive Decline: The  
533 SILCODE Study. *J Alzheimers Dis* **82**, 513–526 (2021).
- 534 52. Chen, G., Zhou, X., Zhu, Y., Shi, W. & Kong, L. Gut microbiome characteristics in subjective  
535 cognitive decline, mild cognitive impairment and Alzheimer’s disease: a systematic review and  
536 meta-analysis. *Eur J Neurol* **30**, 3568–3580 (2023).
- 537 53. Reisberg, B., Shulman, M. B., Torossian, C., Leng, L. & Zhu, W. Outcome over seven years of  
538 healthy adults with and without subjective cognitive impairment. *Alzheimers Dement* **6**,  
539 10.1016/j.jalz.2009.10.002 (2010).
- 540 54. Dekkers, K. F. *et al.* An online atlas of human plasma metabolite signatures of gut microbiome  
541 composition. *Nat Commun* **13**, 5370 (2022).
- 542 55. Simfukwe, C., Youn, Y. C., Kim, M.-J., Paik, J. & Han, S.-H. CNN for a Regression Machine  
543 Learning Algorithm for Predicting Cognitive Impairment Using qEEG. *Neuropsychiatric Disease*  
544 *and Treatment* **19**, 851–863 (2023).
- 545 56. Subramanyam Rallabandi, V. P. & Seetharaman, K. Deep learning-based classification of healthy  
546 aging controls, mild cognitive impairment and Alzheimer’s disease using fusion of MRI-PET  
547 imaging. *Biomedical Signal Processing and Control* **80**, 104312 (2023).
- 548 57. Zubrikhina, M. O. *et al.* Machine learning approaches to mild cognitive impairment detection  
549 based on structural MRI data and morphometric features. *Cognitive Systems Research* **78**, 87–95  
550 (2023).

- 551 58. Tong, T., Gray, K., Gao, Q., Chen, L. & Rueckert, D. Multi-modal classification of Alzheimer's  
552 disease using nonlinear graph fusion. *Pattern Recognition* **63**, 171–181 (2017).
- 553 59. Purser, J. L., Fillenbaum, G. G. & Wallace, R. B. Memory complaint is not necessary for  
554 diagnosis of mild cognitive impairment and does not predict 10-year trajectories of functional  
555 disability, word recall, or short portable mental status questionnaire limitations. *J Am Geriatr Soc*  
556 **54**, 335–338 (2006).
- 557 60. Geerlings, M. I., Jonker, C., Bouter, L. M., Adèr, H. J. & Schmand, B. Association between  
558 memory complaints and incident Alzheimer's disease in elderly people with normal baseline  
559 cognition. *Am J Psychiatry* **156**, 531–537 (1999).
- 560 61. Playdon, M. C. *et al.* Comparing metabolite profiles of habitual diet in serum and urine. *Am J*  
561 *Clin Nutr* **104**, 776–789 (2016).
- 562 62. Bendheim, P. E. *et al.* Development of indole-3-propionic acid (OXIGON) for Alzheimer's  
563 disease. *J Mol Neurosci* **19**, 213–217 (2002).
- 564 63. Chyan, Y. J. *et al.* Potent neuroprotective properties against the Alzheimer beta-amyloid by an  
565 endogenous melatonin-related indole structure, indole-3-propionic acid. *J Biol Chem* **274**, 21937–  
566 21942 (1999).
- 567 64. Cheng, X. & van Breemen, R. B. Mass spectrometry-based screening for inhibitors of beta-  
568 amyloid protein aggregation. *Anal Chem* **77**, 7012–7015 (2005).
- 569 65. Kim, C.-S., Jung, S., Hwang, G.-S. & Shin, D.-M. Gut microbiota indole-3-propionic acid  
570 mediates neuroprotective effect of probiotic consumption in healthy elderly: A randomized,  
571 double-blind, placebo-controlled, multicenter trial and in vitro study. *Clinical Nutrition* **42**, 1025–  
572 1033 (2023).
- 573 66. Rothhammer, V. *et al.* Type I interferons and microbial metabolites of tryptophan modulate  
574 astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. *Nat*  
575 *Med* **22**, 586–597 (2016).
- 576 67. Garcez, M. L., Tan, V. X., Heng, B. & Guillemin, G. J. Sodium Butyrate and Indole-3-propionic  
577 Acid Prevent the Increase of Cytokines and Kynurenine Levels in LPS-induced Human Primary  
578 Astrocytes. *Int J Tryptophan Res* **13**, 1178646920978404 (2020).

- 579 68. Gao, J. *et al.* The Association of Fried Meat Consumption With the Gut Microbiota and Fecal  
580 Metabolites and Its Impact on Glucose Homeostasis, Intestinal Endotoxin Levels, and Systemic  
581 Inflammation: A Randomized Controlled-Feeding Trial. *Diabetes Care* **44**, 1970–1979 (2021).
- 582 69. Terry, N. & Margolis, K. G. Serotonergic Mechanisms Regulating the GI Tract: Experimental  
583 Evidence and Therapeutic Relevance. *Handb Exp Pharmacol* **239**, 319–342 (2017).
- 584 70. Rao, M. & Gershon, M. D. The bowel and beyond: the enteric nervous system in neurological  
585 disorders. *Nat Rev Gastroenterol Hepatol* **13**, 517–528 (2016).
- 586 71. Chalazonitis, A. & Rao, M. Enteric nervous system manifestations of neurodegenerative disease.  
587 *Brain Res* **1693**, 207–213 (2018).
- 588 72. Willette, A. A. *et al.* Inflammation, negative affect, and amyloid burden in Alzheimer’s disease:  
589 Insights from the kynurenine pathway. *Brain, Behavior, and Immunity* **95**, 216–225 (2021).
- 590 73. Franco, Á. de O., Starosta, R. T. & Roriz-Cruz, M. The specific impact of uremic toxins upon  
591 cognitive domains: a review. *J Bras Nefrol* **41**, 103–111 (2019).
- 592 74. Iwata, K. *et al.* Involvement of indoxyl sulfate in renal and central nervous system toxicities  
593 during cisplatin-induced acute renal failure. *Pharm Res* **24**, 662–671 (2007).
- 594 75. Hou, Y.-C., Lu, K.-C., Huang, C.-L., Lin, Y.-F. & Chen, R.-M. Serum albumin and indoxyl  
595 sulfate were predictive of cognitive impairment via amyloid beta and tauopathy, respectively, in  
596 end-stage renal disease patients. *Alzheimer’s & Dementia* **17**, e053921 (2021).
- 597 76. Zheng, L. J. *et al.* Gut dysbiosis-influence on amygdala-based functional activity in patients with  
598 end stage renal disease: a preliminary study. *Brain Imaging Behav* **14**, 2731–2744 (2020).
- 599 77. Hahn, B., Reneski, C. H., Pocivavsek, A. & Schwarcz, R. Prenatal kynurenine treatment in rats  
600 causes schizophrenia-like broad monitoring deficits in adulthood. *Psychopharmacology (Berl)*  
601 **235**, 651–661 (2018).
- 602 78. Pocivavsek, A. *et al.* Fluctuations in endogenous kynurenic acid control hippocampal glutamate  
603 and memory. *Neuropsychopharmacology* **36**, 2357–2367 (2011).
- 604 79. Fazio, F. *et al.* Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a  
605 Potential Trait Marker for Schizophrenia. *Sci Rep* **5**, 17799 (2015).

- 606 80. Chiappelli, J. *et al.* Stress-induced increase in kynurenic acid as a potential biomarker for patients  
607 with schizophrenia and distress intolerance. *JAMA Psychiatry* **71**, 761–768 (2014).
- 608 81. Stone, T. W. & Darlington, L. G. The kynurenine pathway as a therapeutic target in cognitive and  
609 neurodegenerative disorders. *Br J Pharmacol* **169**, 1211–1227 (2013).
- 610 82. Fujigaki, H., Yamamoto, Y. & Saito, K. L-Tryptophan-kynurenine pathway enzymes are  
611 therapeutic target for neuropsychiatric diseases: Focus on cell type differences.  
612 *Neuropharmacology* **112**, 264–274 (2017).
- 613 83. Marrugo-Ramírez, J., Rodríguez-Núñez, M., Marco, M.-P., Mir, M. & Samitier, J. Kynurenic  
614 Acid Electrochemical Immunosensor: Blood-Based Diagnosis of Alzheimer’s Disease.  
615 *Biosensors* **11**, 20 (2021).
- 616 84. Zeisel, S. H. & da Costa, K.-A. Choline: An Essential Nutrient for Public Health. *Nutr Rev* **67**,  
617 615–623 (2009).
- 618 85. Dave, N. *et al.* Dietary choline intake is necessary to prevent systems-wide organ pathology and  
619 reduce Alzheimer’s disease hallmarks. *Aging Cell* **22**, e13775 (2023).
- 620 86. Wurtman, R. J., Cansev, M. & Ulus, I. H. Choline and Its Products Acetylcholine and  
621 Phosphatidylcholine. in *Handbook of Neurochemistry and Molecular Neurobiology: Neural*  
622 *Lipids* (eds. Lajtha, A., Tettamanti, G. & Goracci, G.) 443–501 (Springer US, Boston, MA,  
623 2009). doi:10.1007/978-0-387-30378-9\_18.
- 624 87. Poly, C. *et al.* The relation of dietary choline to cognitive performance and white-matter  
625 hyperintensity in the Framingham Offspring Cohort1234. *Am J Clin Nutr* **94**, 1584–1591 (2011).
- 626 88. Cai, Y.-Y. *et al.* Integrated metagenomics identifies a crucial role for trimethylamine-producing  
627 *Lachnoclostridium* in promoting atherosclerosis. *npj Biofilms Microbiomes* **8**, 1–12 (2022).
- 628

629 **Table 1: Baseline characteristics of the participants.** Mean (SD). P-value calculated using one-way ANOVA.  
 630 Significant values at p<0.05 are in bold. SCI: subjective cognitive impairment, MCI: mild cognitive impairment,  
 631 TMT: Trail Making Test A or B. Bold p-values represent p<0.05.

632

	<b>Control (N=50)</b>	<b>SCI (N=50)</b>	<b>MCI (N=50)</b>	<b>P-value</b>
Sex, M/ F (%F)	23/27 (54)	23/27 (54)	23/27 (54)	-
Age (years)	65.6 (5.3)	65.5 (6.1)	65.5 (5.8)	0.999
BMI (kg/m <sup>2</sup> )	25.1 (3.1)	25.0 (2.9)	25.0 (2.8)	0.993
Education (years)	14.4 (2.6)	14.6 (4.0)	14.6 (3.9)	0.968
% <i>APOE4</i>	18	26	38	0.079
<b>Cognitive tests</b>				
TMT A	30.7 (6.2)	29.3 (8.1)	33.3 (12.1)	0.088
TMAT B	66.4 (20.4)	62.3 (16.5)	74.9 (27.3)	<b>0.015</b>
Digit Span Forwards	11.1 (2.2)	11.2 (1.8)	10.5 (2.6)	0.211
Digit Span Backwards	7.7 (2.0)	7.2 (1.8)	6.5 (2.1)	<b>0.011</b>
Digit Span Total	18.8 (3.8)	18.4 (3.0)	17.0 (4.2)	<b>0.039</b>
<b>Biochemistry</b>				
Creatinine (µmol/L)	73.90 (13.5)	72.5 (12.3)	73.5 (14.1)	0.871
Albumin (g/L)	40.4 (2.4)	30.0 (2.4)	39.4 (2.3)	<b>&lt;0.001</b>
Bilirubin (µmol/L)	12.8 (4.7)	8.9 (5.1)	9.1 (4.4)	<b>&lt;0.001</b>
AST (µL)	21.7 (3.9)	20.6 (5.9)	24.0 (13.1)	0.141
ALT (µL)	16.9 (5.4)	16.7 (9.0)	18.3 (11.3)	0.621
AST/ALT	1.4 (0.3)	1.4 (0.4)	1.4 (0.4)	0.548
Fasting Glucose (mmol/L)	4.8 (0.4)	5.0 (0.5)	5.3 (1.0)	<b>&lt;0.001</b>
Triglyceride (mmol/L)	1.1 (0.5)	1.1 (0.4)	1.2 (0.5)	0.368
Cholesterol (mmol/L)	5.6 (1.1)	5.2 (1.1)	5.2 (1.0)	0.174
HDL Cholesterol (mmol/L)	1.6 (0.4)	1.5 (0.5)	1.5 (0.4)	0.297
LDL Cholesterol (mmol/L)	3.4 (0.1)	3.2 (0.9)	3.1 (0.8)	0.182

633













634  
635  
636  
637




**Table 2:** Multiple linear regression model (adjusted for age, BMI, liver function (AST/ALT ratio), kidney function (creatinine) and diet) showing metabolites significantly associated with early cognitive decline. Diet was analysed using hierarchical clustering, ‘Ward’ method, to group individuals with similar dietary patterns. This grouped participants into three dietary groups (low, moderate and high intake of dietary components (Kcal, carbohydrates, fats, protein, water, alcohol, minerals, vitamins). Healthy controls and diet group 2 (moderate intake) were used as reference groups in the model. Bold p-values represent  $p < 0.05$ .

Explanatory Variable	Metabolite																			
	Indoxyl Sulfate				Choline				5-Hydroxyindole Acetic Acid				Indole Propionic Acid				Kynurenic Acid			
	Beta	P-value	95% CI		Beta	P-value	95% CI		Beta	P-value	95% CI		Beta	P-value	95% CI		Beta	P-value	95% CI	
			Low	High			Low	High			Low	High			Low	High			Low	High
Constant	-2.288	0.482	-8.705	4.128	29.690	<b>0.011</b>	6.938	52.443	0.068	<b>0.020</b>	0.011	0.125	3.094	<b>0.009</b>	0.790	5.397	0.017	0.448	-0.027	0.062
Age	0.057	0.115	-0.014	0.128	0.100	0.434	-0.152	0.351	0.001	0.058	0.000	0.001	-0.007	0.568	-0.033	0.018	<0.001	0.314	-0.001	<0.001
BMI	0.064	0.378	-0.079	0.207	-0.328	0.202	-0.835	0.178	-0.001	0.063	-0.003	0.000	-0.026	0.308	-0.077	0.025	0.001	<b>0.039</b>	<0.001	0.002
Creatinine	0.036	<b>0.028</b>	0.004	0.067	0.105	0.063	-0.006	0.217	0.000	0.493	0.000	0.000	-0.004	0.452	-0.016	0.007	0.001	<b>&lt;0.001</b>	<0.001	0.001
AST/ALT	-1.437	<b>0.011</b>	-2.541	-0.332	0.812	0.681	-3.082	4.706	-0.002	0.710	-0.012	0.008	0.213	0.289	-0.182	0.607	-0.009	<b>0.023</b>	-0.017	-0.001
Diet Group 1	0.354	0.445	-0.559	1.267	1.247	0.445	-1.972	4.466	-0.002	0.690	-0.010	0.006	0.204	0.221	-0.124	0.532	-0.003	0.408	-0.009	0.004
Diet Group 3	0.130	0.829	-1.052	1.311	-0.706	0.740	-4.897	3.486	-0.001	0.826	-0.012	0.009	-0.128	0.568	-0.570	0.314	-0.003	0.450	-0.011	0.005
SCI	1.650	<b>0.001</b>	0.674	2.625	-5.635	<b>0.002</b>	-9.084	-2.187	-0.011	<b>0.012</b>	-0.020	-0.002	-0.181	0.316	-0.536	0.174	0.007	<b>0.037</b>	<0.001	0.014
MCI	1.308	<b>0.008</b>	0.342	2.274	-5.217	<b>0.003</b>	-8.645	-1.789	-0.015	<b>0.001</b>	-0.024	-0.007	-0.558	<b>0.002</b>	-0.910	-0.206	0.001	0.874	-0.006	0.007
Overall change in early cognitive decline	Increased				Decreased				Decreased				Decreased				Increased			







**A****B****C****D**

Pair	F-value	R-Squared	P-value	FDR
Control vs SCI	1.77	0.02	0.01 *	0.03 *
SCI vs MCI	1.02	0.01	0.38	0.38
MCI vs Control	1.26	0.01	0.10	0.15

Scores Plot

